Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis

N. Pipitone, A. Versari, A. Vaglio, Carlo Salvarani

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Retroperitoneal fibrosis is a syndrome characterised by the presence of fibrosclerotic tissue in the retroperitoneum, often encasing the ureters. In most cases, retroperitoneal fibrosis is idiopathic, but may also be associated with large-vessel vasculitis at distant sites, with the so-called IgG4-related sclerosing disease, as well as with exposure to some medications, infections, malignancies, surgery, or radiation. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a nuclear medicine technique which is able to accurately identify in vivo areas characterised by elevated glucose metabolism, such as inflammatory, infective, and neoplastic lesions. There is mounting evidence suggesting that FDG-PET may have a role in assessing disease activity in idiopathic retroperitoneal fibrosis, but the role of FDG-PET in secondary retroperitoneal fibrosis is less established. Herein, we present four patients with retroperitoneal fibrosis of different etiology (isolated idiopathic, associated with large-vessel involvement, associated with carcinoid tumour, and secondary to pergolide) who underwent FDG-PET as part of their workup. The implications of FGD-PET results in the diagnosis and treatment of retroperitoneal fibrosis of different etiology are discussed.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume29
Issue number1 SUPPL. 64
Publication statusPublished - 2011

Fingerprint

Retroperitoneal Fibrosis
Fluorodeoxyglucose F18
Positron-Emission Tomography
Pergolide
Nuclear Medicine
Carcinoid Tumor
Ureter
Vasculitis
Immunoglobulin G
Radiation
Glucose
Infection
Neoplasms

Keywords

  • Chronic periaortitis
  • PET
  • Retroperitoneal fibrosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis. / Pipitone, N.; Versari, A.; Vaglio, A.; Salvarani, Carlo.

In: Clinical and Experimental Rheumatology, Vol. 29, No. 1 SUPPL. 64, 2011.

Research output: Contribution to journalArticle

@article{b34d39b21f2744b58ca448769f0fc106,
title = "Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis",
abstract = "Retroperitoneal fibrosis is a syndrome characterised by the presence of fibrosclerotic tissue in the retroperitoneum, often encasing the ureters. In most cases, retroperitoneal fibrosis is idiopathic, but may also be associated with large-vessel vasculitis at distant sites, with the so-called IgG4-related sclerosing disease, as well as with exposure to some medications, infections, malignancies, surgery, or radiation. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a nuclear medicine technique which is able to accurately identify in vivo areas characterised by elevated glucose metabolism, such as inflammatory, infective, and neoplastic lesions. There is mounting evidence suggesting that FDG-PET may have a role in assessing disease activity in idiopathic retroperitoneal fibrosis, but the role of FDG-PET in secondary retroperitoneal fibrosis is less established. Herein, we present four patients with retroperitoneal fibrosis of different etiology (isolated idiopathic, associated with large-vessel involvement, associated with carcinoid tumour, and secondary to pergolide) who underwent FDG-PET as part of their workup. The implications of FGD-PET results in the diagnosis and treatment of retroperitoneal fibrosis of different etiology are discussed.",
keywords = "Chronic periaortitis, PET, Retroperitoneal fibrosis",
author = "N. Pipitone and A. Versari and A. Vaglio and Carlo Salvarani",
year = "2011",
language = "English",
volume = "29",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "1 SUPPL. 64",

}

TY - JOUR

T1 - Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis

AU - Pipitone, N.

AU - Versari, A.

AU - Vaglio, A.

AU - Salvarani, Carlo

PY - 2011

Y1 - 2011

N2 - Retroperitoneal fibrosis is a syndrome characterised by the presence of fibrosclerotic tissue in the retroperitoneum, often encasing the ureters. In most cases, retroperitoneal fibrosis is idiopathic, but may also be associated with large-vessel vasculitis at distant sites, with the so-called IgG4-related sclerosing disease, as well as with exposure to some medications, infections, malignancies, surgery, or radiation. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a nuclear medicine technique which is able to accurately identify in vivo areas characterised by elevated glucose metabolism, such as inflammatory, infective, and neoplastic lesions. There is mounting evidence suggesting that FDG-PET may have a role in assessing disease activity in idiopathic retroperitoneal fibrosis, but the role of FDG-PET in secondary retroperitoneal fibrosis is less established. Herein, we present four patients with retroperitoneal fibrosis of different etiology (isolated idiopathic, associated with large-vessel involvement, associated with carcinoid tumour, and secondary to pergolide) who underwent FDG-PET as part of their workup. The implications of FGD-PET results in the diagnosis and treatment of retroperitoneal fibrosis of different etiology are discussed.

AB - Retroperitoneal fibrosis is a syndrome characterised by the presence of fibrosclerotic tissue in the retroperitoneum, often encasing the ureters. In most cases, retroperitoneal fibrosis is idiopathic, but may also be associated with large-vessel vasculitis at distant sites, with the so-called IgG4-related sclerosing disease, as well as with exposure to some medications, infections, malignancies, surgery, or radiation. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a nuclear medicine technique which is able to accurately identify in vivo areas characterised by elevated glucose metabolism, such as inflammatory, infective, and neoplastic lesions. There is mounting evidence suggesting that FDG-PET may have a role in assessing disease activity in idiopathic retroperitoneal fibrosis, but the role of FDG-PET in secondary retroperitoneal fibrosis is less established. Herein, we present four patients with retroperitoneal fibrosis of different etiology (isolated idiopathic, associated with large-vessel involvement, associated with carcinoid tumour, and secondary to pergolide) who underwent FDG-PET as part of their workup. The implications of FGD-PET results in the diagnosis and treatment of retroperitoneal fibrosis of different etiology are discussed.

KW - Chronic periaortitis

KW - PET

KW - Retroperitoneal fibrosis

UR - http://www.scopus.com/inward/record.url?scp=79960425187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960425187&partnerID=8YFLogxK

M3 - Article

C2 - 21418782

AN - SCOPUS:79960425187

VL - 29

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 1 SUPPL. 64

ER -